Juno is a clinical-stage biopharmaceutical company that works by developing cellular immunotherapies and medicines that re-engage the body's immune system in order to treat cancer.
Juno Therapeutics is one of those new cancer immunotherapy, CAR-T biotech names that has lately been on fire.
(Chimeric antigen receptors, or CARs are proteins that allow the T cells to recognize a specific protein, or antigen, on tumor cells)
The stock shows a very strong uptrend of late, and in impressive fashion, has risen sharply on days the market was down. That is strong Relative Strength, indicated by the action in the top pane. We notice a consolidation from the highs in early April that held above the levels where the stock first started trading in December of 2014 ($38 to $40).
Want more like this from Bryan Ashenberg and Bob Lang BEFORE your stock moves? Learn more about Trifecta Stocks now!